Support of research and innovation in health care is one of the few areas of bipartisan agreement in Washington, D.C.
But for innovation to spread, government policies must do more than fund research; these policies must also ensure that patients gain easy access to those innovative treatments. Unfortunately, CMS policies might do the opposite in the case of Korsuva, the medication approved and awarded breakthrough status by the FDA in 2021.
Korsuva (difelikepahlin), a kappa-opioid receptor agonist, is the first and only drug to effectively treat chronic kidney disease-associated pruritus